目的 探讨荆防颗粒联合奥司他韦治疗小儿流感的临床疗效。方法 选取2022年8月—2023月10月在苏州市中西医结合医院诊治的流行性感冒患儿111例，根据治疗方案差异将患儿分成对照组（55例）和治疗组（56例）。对照组患儿口服磷酸奥司他韦颗粒，体质量≤15 kg，30 mg/次，15 kg＜体质量≤23 kg，45 mg/次，23 kg＜体质量≤40 kg，60 mg/次，＞40 kg患儿75 mg/次，2次/d。治疗组在对照组治疗基础上口服荆防颗粒，年龄＜3岁者每次1/4袋，3岁≤年龄＜5岁者每次1/3袋，5岁≤年龄≤10岁者每次1/2袋，年龄＞10岁者1袋/次，3次/d。两组患儿均进行5 d的治疗。观察两组患儿临床疗效，比较治疗前后两组患儿临床症状消失时间，及血清炎症因子超敏C反应蛋白（hs-CRP）、血清淀粉样蛋白A（SAA）和干扰素-γ（IFN-γ）水平。结果 治疗后，对照组和治疗组临床总有效率分别为85.45%、96.43%，两组比较差异具有统计学意义（P＜0.05）。治疗后，治疗组患儿发热恶寒、周身酸痛、咳嗽流涕、咽痛等临床症状消失时间均明显早于对照组（P＜0.05）。治疗后，两组患儿血清炎症因子hs-CRP、SAA、IFN-γ水平均较治疗前显著下降（P＜0.05），且治疗后治疗组炎症因子水平均明显低于对照组（P＜0.05）。结论 荆防颗粒联合奥司他韦治疗小儿流行性感冒的治疗效果显著，不仅能够显著改善患儿临床症状，同时还能够促进体内炎症水平的修复。

Objective To explore the clinical efficacy of Jingfang Granules combined with oseltamivir in treatment of children with influenza. Methods Children (111 cases) with influenza in Suzhou Hospital of Integrated Traditional Chinese and Western Medicine from August 2022 to October 2023 were divided into control (55 cases) and treatment (56 cases) group based on different treatments. Children in the control group were po administered with Oseltamivir Phosphate Granules, body mass ≤15 kg, 30 mg/time, 15 kg < body mass ≤ 23 kg, 45 mg/time, 23 kg < body mass ≤ 40 kg, 60 mg/time, body mass > 40 kg, 75 mg/time, twice daily. Children in treatment group were po administered with Jingfang Granules on basis of control group, < 3 years old, 1/4 bag/time, 3 years ≤ age < 5 years, 1/3 bag/time, 5 years ≤ age ≤ 10 years, 1/2 bag/time, > 10 years, 1 bag/time, 3 times daily. Children in two groups were treated for 5 d. After treatment, the clinical evaluations were evaluated, the disappearance time of clinical symptoms, the levels of serum hs-CRP, SAA and IFN-γ in two groups before and after treatment were compared. Results After treatment, the total clinical effective rates in the control group and the treatment group were 85.45% and 96.43%, respectively, and the difference between the two groups was statistically significant (P < 0.05). After treatment, the disappearance time of clinical symptoms such as fever and aversion to cold, body aches, coughing and runny nose, and sore throat in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the levels of serum inflammatory factors hs-CRP, SAA, and IFN-γ in two groups were significantly decreased compared with those before treatment (P < 0.05), and the levels of inflammatory factors in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Jingfang Granule combined with oseltamivir has a significant therapeutic effect on children with influenza. It can not only significantly improve the clinical symptoms of children, but also promote the repair of the level of inflammation.

R974;R985